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Abstract
Background: High throughput proteomic technology offers promise for the detection of disease
biomarkers and proteomic signature patterns but biomarker discovery studies can be limited by
cost factors when large sample size numbers are required. Pooling sera or plasma samples from
disease cases potentially offers a solution to cost implications by reducing the standard errors of
mass to charge values. Surface enhanced laser desorption/ionization time of flight (SELDI-ToF) mass
spectra obtained from individual and pooled sera from invasive aspergillosis cases and controls
were compared.
Results: Pooling resulted in 50% loss of peak clusters detected in individual samples. Overall, loss
was greatest for low intensity clusters. Peak intensities and case:control intensity ratios, among
clusters not lost, demonstrated good reproducibility.
Conclusion: Pooling sera results in significant potential biomarker loss when using SELDI-ToF MS.
Background
High throughput proteomic technology has increasingly
been used for the detection of disease biomarkers and
proteomic signature patterns have potential diagnostic
value [1]. However biomarker discovery studies can be
limited by cost factors when large sample size numbers
are required. Surface enhanced laser desorption/ioniza-
tion time of flight mass spectrometry (SELDI-ToF MS) [2]
is a high-throughput proteomic profiling platform that
has reasonable reproducibility if strict quality control pro-
cedures are observed [3]. Potential biomarkers in sera or
tissue are often found at very low and variable concentra-
tions and finding robust disease associations for them is a
major challenge [4]. Pre-fractionation of samples by ion-
exchange chromatography, coupled with further on-chip
fractionation by the SELDI method, improves detection of
low abundance protein species but requires larger num-
bers of array experiments, pushing up costs further.
One proposed way in which to address the challenge of
cost is to pool patient samples during the discovery phase.
In theory by pooling equal volumes of sera from cases and
similarly from controls, the potential loss of statistical
power arising from reduced sample size is theoretically
offset by the reduction in the standard error of the means
of individual protein mass to charge (m/z) values (peak
clusters), as long as the reduction in sample size is not too
marked. However it is unclear as to whether the process of
pooling itself actually results in simple averaging of pro-
tein concentrations because of potential biological or bio-
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chemical interactions, although this would be less likely if
samples are denatured prior to pooling. Importantly for
biomarker discovery, ratios of the biomarker concentra-
tions in cases compared to controls found in individual
samples would need to be maintained when pooled sam-
ple analysis is performed.
The aim of this study was to investigate the consistency of
potential biomarker detection and variation in intensities
for individual peak clusters obtained from SELDI-ToF
before and after pooling serum samples.
Methods
Generation of mass spectra
Equal volumes of sera from 20 patients with proven inva-
sive aspergillosis (an opportunistic fungal infection affect-
ing immunocompromised patients) and 20 controls with
non-fungal causes of sepsis, were pooled to form case and
control pooled samples. After denaturation for 30 min-
utes on ice (10 μl pooled or individual serum diluted 1:10
v/v in 9 M urea/2% CHAPS/2 mM DTT/50 mM Trizma
base (pH 9.0)), samples were further diluted 1:10 v/v in
binding buffer (100 mmol/L ammonium acetate, 0.1%
Triton-X100, pH 4.0), and immediately spotted in dupli-
cate on CM10 weak cation exchange arrays (Ciphergen
Inc, CA), pre-equilibrated with binding buffer, in a bio-
processor (100 μL/well). The bioprocessor was sealed and
incubated at room temperature on a shaker (300 rpm) for
1 hr after which the protein chip arrays were washed three
times in binding buffer, twice in wash buffer (100 mmol/
L ammonium acetate, pH4.0) and finally in water (5 min-
utes/wash). Mass spectra were generated by SELDI-ToF MS
using a Proteinchip reader PBSIIc (Ciphergen Inc, CA) as
described previously [5,6]. The pooled serum samples
were run at the same time, on the same SELDI-ToF mass
spectrometer as individual (non-pooled) samples, with-
out any intervening period of storage and were inter-
spersed among individual samples on the same
proteinchip arrays. Spectra were generated at a laser inten-
sity of 215, high mass 100 kDa, detector sensitivity 8, and
focus mass 10 kDa (for low mass range) and 50 kDa (high
mass range). Spectra were baseline-subtracted and nor-
malised to total ion current. Samples were re-run or
excluded if their normalisation factor (NF) fell outside 2
SDs from the mean NF. The instrument was calibrated for
the m/z ranges 2500 – 20,000 and 20,000–100,000 using
two pre-mixed sets of external standards; All-in-one Pep-
tide Standard (Ciphergen In., CA) and All-in-One Protein
Standard (Ciphergen Inc., CA), respectively. To assess
technical reproducibility, a single quality control serum
sample collected and aliquoted from 1 healthy volunteer
was run repeatedly at random spot positions on 7 separate
CM10 protein chip arrays on the same day as the individ-
ual and pooled samples. The pooled coefficients of varia-
tion (CVp) for intensity for all peaks with S/N > 5, present
in 100% of replicates, were 17.3% (degrees of freedom
222) for the m/z range 2,500 – 20,000 (37 peaks) and
17.6% (df 48) for the m/z  range 20,000–100,000 (8
peaks). CVps for m/z in the same m/z ranges were 0.03%
and 0.05%, respectively. These values are consistent with
those reported in the literature and with the manufac-
turer's specifications.
Peak clustering
Peak clusters are m/z values deemed to represent corre-
sponding peaks across all spectra. After baseline subtrac-
tion and normalisation to total ion current, peak clusters
were generated from the individual sample spectra using
Biomarker Wizard (range 2,500 – 100,000, 1st pass S/N 5,
2nd pass S/N 2, cluster mass window 0.3%). As a further
quality control measure, a further set of clusters was gen-
erated using the same parameters, specifically across the
mass range of 20,000–100,000 but using a wider mass
window of 0.6% in order to check that the sensitivity of
cluster detection was not significantly affected using a
mass window of 0.3% at the higher mass range. Average
peak intensities were calculated from the duplicate spots.
There are 2 ways of identifying corresponding peak clus-
ters in the individual and pooled sets of spectra. Peaks can
be detected de novo in the pooled spectra using the same
detection criteria as for individual spectra. Alternatively,
the peak clusters derived from the individual spectra can
be 'superimposed' on the pooled spectra to provide an
intensity value for every notional peak cluster, regardless
of whether it is actually represented in the pooled spectra.
Because we wanted to examine the effects of pooling on
the detectability and intensity of peaks, we used both
approaches. 'Set A' was generated by performing de novo
peak clustering on the pooled spectra and 'Set B' by
imposing peak clusters derived from the individual spec-
tra, as summarised in figure 1.
Peak-cluster sets analysed in this study Figure 1
Peak-cluster sets analysed in this study.
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Because peak clusters obtained from set A did not always
align precisely with probable corresponding clusters
obtained from the individual spectra, it was necessary to
perform a secondary clustering procedure to define corre-
sponding peaks. Thus peak clusters from the individual
and pooled samples that were closest and that fell within
0.3% m/z of each other were deemed to correspond to one
another and were 'retained' for comparative analysis of
mean intensities. Peaks falling outside this criterion were
considered to be unique to either pooled or individual
spectra. For both sets ('retained' values only for set A)
mean intensities for each peak cluster in the pooled and
individual spectra sets were compared. This comparison
was expressed as the median number (and interquartile
range) of individual sample standard deviations (SDs)
that pooled sample intensities lay from their respective
individual sample means. This was done separately for
cases and controls. In addition, for each peak cluster the
ratios of the case mean intensity to control mean intensity
in the individual samples were calculated and the devia-
tion of this ratio for corresponding peaks in the pooled
samples was expressed as the number of standard errors of
the mean that pooled sample ratios lay from individual
sample ratios [7]. The variation of the most significant
biomarkers detected (p < 0.05, by Mann-Whitney U test)
was also calculated.
Results
Representative spectra obtained from quality control,
individual case and control and pooled case and control
spectra are shown in figure 2. Where peaks in the pooled
spectra were defined independently from peaks in the
individual spectra (set A), 197 and 110 peak clusters were
detected from the individual and pooled sample experi-
ments respectively. 97 (49.2%) peak clusters fulfilled the
pre-defined criterion of being within 0.3% of their m/z
values between pooled and individual samples and were
retained for comparative analysis (figure 3). Pooling
resulted in the 'loss' of 100 peak clusters, while 13 peak
clusters appeared to be unique to the pooled samples. In
the quality control replicates, 44/55 (80%) of peaks with
m/z > 2500 detected at a S/N ≥ 5 and a mass window of
0.3%, were present in all 7 replicates. Only a few clusters
were generated across the mass range of 20,000 to
100,000 using a mass window of 0.3% and this hardly
changed when using a mass window of 0.6% over the
same range (data not shown).
Among these retained peak clusters, pooled-sample case
and control intensities and case:control intensity ratios
varied little from their respective values in individual sam-
ples. Of the pooled-sample case and control intensities,
all lay <1 SD from their respective individual sample
means, apart from 6/97 cases (which lay between 1 and 2
SDs) and 3/97 controls (which lay between 1 and 2 SDs).
The case:control intensity ratios in the pooled samples
were highly comparable to their corresponding ratios cal-
culated from peak intensity means in the individual sam-
ples; all lay less than 1 SE from their values in the
individual samples, apart from 1/97 which lay just over
one SEs from its corresponding individual sample ratio).
59/97 (61%) of pooled sample case:control intensity
ratios were less than 0.25 SEs from their respective indi-
vidual sample intensity ratios.
Of the potentially discriminating peak clusters whose
intensities differed statistically significantly between cases
and controls, 21/35 (60%) were retained for analysis i.e.
14 were 'lost' as a result of pooling. Among these surviving
clusters, a reduction in variation of intensities and ratios
was observed (see figure 4 and Table 1). Pooled sample
spectra were examined and potential peaks, falling within
a 0.3% mass window of the individual sample clusters,
but not identified by Biomarker wizard, were labeled
manually for the 14/35 statistically significant peak clus-
ters not retained for analysis. When these manually-
labeled peak clusters were included in the data very little
change in variation between pooled and individual sam-
ples was observed (see Table 1).
Factors associated with 'loss' of peak clusters as a result of
pooling in set A were determined. Overall, median
retained m/z values were lower than those not retained
(4476 vs 6163 p = 0.01). Of interest, the 13 peak clusters
observed in pooled samples only and not in individual
samples appeared to have higher m/z values (median m/z
10165) than retained samples but the small numbers pre-
cluded statistical testing (see figure 5). Retention of peak
clusters was more likely when they were found in a higher
proportion of individual samples (median percentage
representation in individual samples for retained vs non-
retained clusters: 75% vs  35%, p < 0.00001; 58% vs
31.5%, p < 0.0004 in patients with peak intensities less
than 1.0). Retention was also associated with higher peak
intensities in both cases and controls, independently of
whether the peak cluster was found in a higher proportion
of individual samples. For retained vs  not-retained,
median (IQR) intensities were 2.55 (1.12 – 4.31) vs 0.75
(0.42 – 1.60) and 2.61 (1.25 – 4.93) vs 0.87 (0.50 – 1.41)
for cases and controls respectively (p < 0.00001 for all
comparisons). For peak clusters that were found in 50%
or more individual samples, these differences were main-
tained (data not shown) indicating that low intensity
peak clusters were lost despite being present in a signifi-
cant proportion of samples.
Of the small number of statistically significant discrimina-
tory peak clusters, there were no detectable differences in
m/z  values between retained and non-retained clusters
(m/z 3451.2 vs 5073 respectively p = 0.171) and againProteome Science 2008, 6:16 http://www.proteomesci.com/content/6/1/16
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retention of peak clusters was much more likely if they
were found in a higher proportion of individual samples
(median percentage: 93% (65–98) vs 35% (21–51); p <
0.00001 for retained vs non-retained for all sera). Reten-
tion of discriminatory peak clusters was also associated
with higher peak intensities in both cases and controls.
Representative SELDI spectra, illustrating a quality control spectrum, 'typical' individual case and control spectra and pooled  sample spectra from the case and control groups Figure 2
Representative SELDI spectra, illustrating a quality control spectrum, 'typical' individual case and control spectra and pooled 
sample spectra from the case and control groups. For each of the pooled sets, the 20 individual samples in each group were 
combined to form a pooled sample, from which a spectrum was generated under the same conditions as for individual samples.
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For retained vs  non-retained, median (IQR) intensities
were 2.0 (1.3 – 3.6) vs 0.6 (0.2 – 1.1) and 3.0 (1.4 – 6.6)
vs 0.9 (0.2 – 1.2) for cases and controls respectively (p <
0.00001).
For set B, in which clusters generated from individual
sample spectra were 'imposed' on pooled sample spectra,
the same patterns were observed compared with set A with
regard to case and control intensities. Imposed clusters
appeared to increase variation of calculated pooled sam-
ple ratios (see Table 1).
Discussion
This study set out to investigate the consistency of poten-
tial biomarker detection when individual case or control
serum samples are pooled. Overall there was reasonable
reproducibility of data between pooled and individual
samples. Peak clusters that were consistently present in
individual spectra and pooled spectra were of comparable
intensities. Moreover, intensity ratios between cases and
controls were largely preserved when measured in pooled
spectra. However, a large proportion of peak clusters were
lost after pooling. The majority of non-retained peak clus-
ters were found only in a minority of individual samples
and were generally associated with very low peak intensi-
ties. A plausible explanation for their loss would be dilu-
tion out during pooling, resulting in their falling below
the noise threshold in the pooled sample. This 'averaging
out' of what could be deemed to be outliers in the pooled
sets may be useful, providing cases and controls are gener-
ally fairly homogeneous. On the other hand, it may
obscure otherwise important differences between subsets
of cases or controls that would be apparent on inspection
of individual spectra at particular peak cluster values. This
would be a significant limitation for the development of
proteomic signature patterns. Importantly, our data sug-
gest that low abundance proteins, even when represented
in a majority of individual samples, may still be lost dur-
ing pooling.
Illustrative individual and pooled spectra showing effects of pooling on peak intensity, resulting in diminished intensity of peak A  and 'loss' of peak B to below the peak detection threshold Figure 4
Illustrative individual and pooled spectra showing effects of pooling on peak intensity, resulting in diminished intensity of peak A 
and 'loss' of peak B to below the peak detection threshold.
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The appearance of 13 'new' peaks in pooled samples
which were not present in the individual sample peak
cluster set, is more difficult to explain. One possibility is
that certain proteolytic interactions may occur in pooled
samples but not individual samples, due to the presence
of proteolytic enzymes in one or more individual sam-
ples. This might result in proteolytic cleavage of proteins
in a pooled set, causing the disappearance of a 'parent'
protein peak and the appearance of 2 or more cleavage
product peaks. The frequency distributions of m/z values
(figure 5) are not inconsistent with a few large proteins
being lost in this manner generating a handful of new
ones in pooled samples, although more work would be
needed to demonstrate this. Proteolysis might be avoided
by denaturing individual samples prior to pooling or by
the inclusion of protease inhibitors, although this adds to
the complexity of the sample pre-processing steps.
A further important limitation of pooling is that it pre-
cludes the development of multivariate classification
models using machine-learning based algorithms such as
support vector machines, artificial neural networks, deci-
sion tree classifiers etc. which require training of classifiers
on individual spectra. Decision tree classifiers, in particu-
lar, are capable of accommodating considerable heteroge-
neity between individual spectra that nevertheless belong
to the same diagnostic category. It is well recognised that
a high degree of inter-individual proteomic variability is
seen in SELDI serum spectra and that multivariate classifi-
ers are a powerful method for assigning spectra to broad
diagnostic groups [8,9]. Pooling will result inevitably in
the loss of individual spectral information.
Conclusion
Taken together, these data suggest that pooling serum
samples may be associated with significant loss of poten-
tial biomarkers using SELDI-ToF MS, despite there being
low variability in intensity for potential biomarkers that
are retained. Concerns exist about the diluting out and
loss of low abundance proteins found in select subsets of
cases and controls. One area in which pooling might be
useful is in the initial selection of chip surface on which to
profile sera. While in ideal circumstances, the most com-
prehensive profile might be achieved by running all sam-
ples on all available chromatographic surfaces, typical
Distribution of m/z values for peak clusters found in both  individual and pooled samples ("retained"), Individual samples  only and Pooled samples only Figure 5
Distribution of m/z values for peak clusters found in both 
individual and pooled samples ("retained"), Individual samples 
only and Pooled samples only. Box = interquartile range, Bar 
= median; whiskers extend only as far as the furthest point 
within 1.5 interquartile ranges below the first quartile or 
above the third quartile. Asterix markers show outliers 
within 3 interquartile ranges above the third quartile, and cir-
cles show outliers beyond 3 interquartile ranges of the third 
quartile. Individual samples and pooled samples n = 100; Indi-
vidual samples n = 97; Pooled samples only n = 13.
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Table 1: Variation of Pooled Sample intensities from Individual Sample intensities, using independent clustering (A) or imposed 
clustering (B). 
Set, Significance level Number of peak 
clusters in pooled 
samples retained for 
analysis
Median number of SDs 
pooled control cluster 
intensities are from 
mean individual sample 
intensities (IQR)
Median number of SDs 
pooled case cluster 
intensities are from 
mean individual sample 
intensities (IQR)
Median number of SEs 
pooled sample case to 
control ratios are from 
means of individual 
sample ratios (IQR)
Proportion of pooled 
sample case to control 
intensity ratios that lie 
less than 0.25 SEs from 
means of individual 
sample ratios
A, all 97/197 (40.9%) 0.37 (0.18 – 0.61) 0.39 (0.16 – 0.62) 0.20 (0.10 – 0.33) 59/97 (61%)
A, p < 0.05 21/35 (60%) 0.29 (0.12 – 0.37) 0.33 (0.17 – 0.44) 0.16 (0.11 – 0.36) 13/22(62%)
A, p < 0.05 (manually 
added peaks, see text)
35/35 (100%) 0.34 (0.16 – 0.56) 0.33(0.18 – 0.57) 0.20 (0.12 – 0.45) 19/35 (54%)
B, all - 0.40 (0.20 – 0.67) 0.43 (0.19 – 0.80) 0.21 (0.11 – 0.43) 109/197 (55%)
B, p < 0.05 - 0.30 (0.19 – 0.46) 0.40 (0.19 – 0.58) 0.14 (0.09 – 0.40) 23/35 (66%)
SD: standard deviation; SE: standard error; SDs and SEs are absolute in value, ignoring direction. IQR: inter-quartile rangePublish with BioMed Central    and   every 
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studies involve the analysis of many hundreds of samples
and cost considerations often preclude such an approach.
The profiling of pooled samples may provide a more reli-
able method for the rapid screening of multiple chroma-
tographic surfaces for potentially discriminating profiles
than merely comparing chip surfaces on the basis of 5–10
individual samples, as is currently common practice.
However, further work, investigating the effects of pooling
on biomarker detection, is warranted and until then,
pooling samples is not a preferred strategy for biomarker
detection.
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